Spots Global Cancer Trial Database for recurrent glioblastoma multiforme
Every month we try and update this database with for recurrent glioblastoma multiforme cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | NCT00290771 | Recurrent Gliob... | Imatinib tablet... Hydroxyurea cap... | 18 Years - | Novartis | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | NCT02062827 | Recurrent Gliob... Progressive Gli... Anaplastic Astr... | M032 (NSC 73397... | 18 Years - | University of Alabama at Birmingham | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | NCT00071539 | Recurrent Gliob... | TP-38 TP38 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | NCT00501891 | Glioblastoma Mu... | Bevacizumab Metronomic Temo... | 18 Years - | Duke University | |
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | NCT04915404 | Recurrent Gliob... | Berubicin Hydro... | 18 Years - | WPD Pharmaceuticals Sp. z o.o. | |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | NCT05868083 | Recurrent Gliob... | SNC-109 CAR-T C... | 18 Years - 70 Years | Shanghai Simnova Biotechnology Co.,Ltd. | |
| Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. | NCT01301430 | Glioblastoma Mu... | H-1PV | 18 Years - | Oryx GmbH & Co. KG | |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | NCT00071539 | Recurrent Gliob... | TP-38 TP38 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | NCT00562419 | Brain and Centr... Recurrent Gliob... | CT-322 irinotecan hydr... | 18 Years - | Adnexus, A Bristol-Myers Squibb R&D Company | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM | NCT03149575 | Glioblastoma Mu... Glioblastoma Glioma GBM Brain Cancer | VAL-083, Dianhy... Physician's Cho... Physician's Cho... Physician's Cho... | 18 Years - | Kintara Therapeutics, Inc. | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | NCT00071539 | Recurrent Gliob... | TP-38 TP38 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | NCT05868083 | Recurrent Gliob... | SNC-109 CAR-T C... | 18 Years - 70 Years | Shanghai Simnova Biotechnology Co.,Ltd. | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) | NCT03463733 | Glioma Glioblastoma | Hydroxyurea Temozolomide | - | Amsterdam UMC, location VUmc | |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | NCT00615927 | Glioblastoma Gliosarcoma | Imatinib Mesyla... | 18 Years - | Duke University | |
| Low Dose Radiation Therapy for Glioblastoma Multiforme | NCT01466686 | High Grade Glio... | Low Dose Fracti... Temozolomide | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | NCT04915404 | Recurrent Gliob... | Berubicin Hydro... | 18 Years - | WPD Pharmaceuticals Sp. z o.o. | |
| Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | NCT02120287 | Glioblastoma Mu... Glioblastoma - ... | Bevacizumab Magnetic Resona... Border Zone Ste... | 18 Years - | University of Pittsburgh | |
| Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme | NCT01464177 | Recurrent Gliob... | Stereotactic hy... Stereotactic hy... | 18 Years - | University of Sao Paulo | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | NCT04915404 | Recurrent Gliob... | Berubicin Hydro... | 18 Years - | WPD Pharmaceuticals Sp. z o.o. | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors | NCT00747253 | Brain Tumor Brain Tumor, Re... Brain Neoplasm Brain Cancer Glioblastoma Mu... Recurrent Gliob... | AutoLITT system | 18 Years - | Monteris Medical | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Low Dose Radiation Therapy for Glioblastoma Multiforme | NCT01466686 | High Grade Glio... | Low Dose Fracti... Temozolomide | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | NCT00104091 | Glioblastoma Mu... | TP-38 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Prospective, Open-label, Single-arm Clinical Study | NCT04689087 | Recurrent Gliob... | TTFields | 18 Years - | Sun Yat-sen University | |
| Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | NCT00306618 | Recurrent Gliob... | Panzem Nanocrys... | 18 Years - | CASI Pharmaceuticals, Inc. | |
| Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | NCT00379470 | Recurrent Gliob... | NovoTTF-100A | 18 Years - | NovoCure Ltd. | |
| Procarbazine and Lomustine in Recurrent Glioblastoma | NCT01737346 | Recurrent Gliob... | lomustine and p... | 20 Years - | Incheon St.Mary's Hospital | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | NCT01478178 | Glioma Glioblastoma Glioblastoma Mu... GBM Brain Cancer | VAL-083 (Dianhy... | 18 Years - | Kintara Therapeutics, Inc. | |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | NCT03423628 | Recurrent Gliob... Primary Gliobla... Brain Neoplasms... Leptomeningeal ... | Radiation Thera... AZD1390 | 18 Years - 130 Years | AstraZeneca | |
| Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) | NCT03463733 | Glioma Glioblastoma | Hydroxyurea Temozolomide | - | Amsterdam UMC, location VUmc | |
| Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | NCT02717962 | Glioma Glioblastoma Glioblastoma Mu... GBM Brain Cancer | VAL-083, Dianhy... | 18 Years - | Kintara Therapeutics, Inc. | |
| A Prospective, Open-label, Single-arm Clinical Study | NCT04689087 | Recurrent Gliob... | TTFields | 18 Years - | Sun Yat-sen University | |
| Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | NCT00306618 | Recurrent Gliob... | Panzem Nanocrys... | 18 Years - | CASI Pharmaceuticals, Inc. | |
| Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | NCT02120287 | Glioblastoma Mu... Glioblastoma - ... | Bevacizumab Magnetic Resona... Border Zone Ste... | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
